Fig. 2: Bioinformatics analysis of the expression and prognostic value of SPATS2 in the TCGA HCC cohort and GEO database. | Cell Death & Disease

Fig. 2: Bioinformatics analysis of the expression and prognostic value of SPATS2 in the TCGA HCC cohort and GEO database.

From: SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle

Fig. 2

(a) Bioinformatics analysis of SPATS2 expression in HCC or non-tumor tissues based on the dataset from TCGA and GEO database. (b) Bioinformatics analysis of SPATS2 expression in normal liver, cirrhotic liver, low- or high-grade dysplastic liver, early or advanced HCC in GSE6764 dataset. (c) Bioinformatics analysis of SPATS2 expression in normal liver, HCC, and portal vein tumor thrombosis in the GSE77509 dataset. (d) Bioinformatics analysis of SPATS2 expression in normal liver, tumor border, and HCC in the GSE84598 dataset. (e) Bioinformatics analysis of SPATS2 expression in HCC tissues with different TNM stages based on the dataset from TCGA. (f, g) Pearson correlation analysis between SPATS2 expression and Ki-67 expression (Pearson’s r = 0.830, p < 0.001) or PCNA expression (Pearson’s r = 0.770, p < 0.001). (h) GSEA analysis of the enrichment of liver cancer survival genes between SPATS2 high expression and low expression groups. (i, j) Kaplan–Meier analysis of the overall survival (OS) and disease-free survival (DFS) of HCC patients with high or low SPATS2 expression in TCGA HCC cohort. (k, l) Kaplan–Meier analysis of OS and DFS of HCC patients with high or low SPATS2 expression at different TNM stages in TCGA HCC cohort. survival. *p < 0.05, **p < 0.01.

Back to article page